NCT04118101View on ClinicalTrials.gov

Erector Spinae Plane Block

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

October 25, 2019

Primary Completion Date

December 10, 2020

Study Completion Date

February 15, 2021

Conditions
Post Operative Pain
Interventions
DRUG

ESPB block

A total of 25 ml bupivacaine 0.5% will be injected into the ESP.

OTHER

control

no ESPB will be given.

Trial Locations (1)

02

Theodor Bilharz research institute, Cairo

All Listed Sponsors
lead

Theodor Bilharz Research Institute

OTHER

NCT04118101 - Erector Spinae Plane Block | Biotech Hunter | Biotech Hunter